Home Clinical Topics FDA approves first therapy for high-risk neuroblastoma

FDA approves first therapy for high-risk neuroblastoma

On March 10, the U.S. Food and Drug Administration (FDA) approved Unituxin (dinutuximab) as part of first-line therapy for pediatric patients with high-risk neuroblastoma. Read more.

LEAVE A REPLY

Please enter your comment!
Please enter your name here